All the news Showing 10 of 141 articles from: Nucleotide Ns5B polymerase inhibitorsGet an RSS feed of these articles Show All news infohep newsEditors' picks from other sources Pharma Execs Don't Know Why Anyone Is Upset by a $94,500 Miracle Cure Bloomberg / 09 June 2015 Sofosbuvir-based therapy effective for hepatitis C patients with decompensated cirrhosis Liz Highleyman / 06 May 2015 Interferon-free regimens containing sofosbuvir (Sovaldi) plus simeprevir (Olysio) cured about three-quarters of people with genotype 1 chronic hepatitis C with advanced cirrhosis and MELD scores >10 in the real-world HCV-TARGET study, researchers reported ... Egypt opens first factory for locally produced Sovaldi News Egypt / 05 May 2015 WHO Issues Guideline For Manufacturers Of Generic Hepatitis C Medicine Intellectual Property Watch / 08 April 2015 Cipla announces the launch of generic drug Sofosbuvir in India under the brand name ‘Hepcvir` Cipla press release / 31 March 2015 Japan’s Ministry of Health, Labour and Welfare Approves Gilead’s Sovaldi® (sofosbuvir) for the Treatment of Genotype 2 Chronic Hepatitis C Gilead press release / 31 March 2015 Sustained virological response represents a long-term cure for people with hepatitis C treated with sofosbuvir Liz Highleyman / 18 March 2015 Almost all patients with hepatitis C virus alone or HIV/HCV co-infection who achieved sustained virological response (SVR) to treatment with sofosbuvir (Sovaldi) plus ribavirin or sofosbuvir/ledipasvir (Harvoni) still had undetectable HCV RNA ... Natco Pharma ties up with Gilead on hepatitis C drugs Reuters / 04 March 2015 The Drug That Is Bankrupting America Huffington Post / 18 February 2015 Interferon-free combination therapy prevents recurrence of HCV after liver transplantation Manual Items / 09 January 2015 ← Prev12345...15Next → Other pages in this section Latest news All the news Hepatitis A Hepatitis B Hepatitis C Hepatitis D Hepatitis E Coronavirus NAFLD Treatment for hepatocellular carcinoma Transmission, epidemiology and prevention Health services, policy and advocacy Social issues Conference news Email bulletin archive